Cargando…

Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy

BACKGROUND: Serum hepatitis B surface antigen (HBsAg) is a component of both hepatitis B virus (HBV) virions and non-infectious subviral particles (SVPs). Recently, O-glycosylation of the PreS2 domain of middle HBsAg protein has been identified as a distinct characteristic of genotype C HBV virions...

Descripción completa

Detalles Bibliográficos
Autores principales: Murata, Ayato, Angata, Kiyohiko, Sogabe, Maki, Sato, Shunsuke, Ichida, Takafumi, Narimatsu, Hisashi, Genda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153111/
https://www.ncbi.nlm.nih.gov/pubmed/35641912
http://dx.doi.org/10.1186/s12876-022-02352-4
_version_ 1784717781692841984
author Murata, Ayato
Angata, Kiyohiko
Sogabe, Maki
Sato, Shunsuke
Ichida, Takafumi
Narimatsu, Hisashi
Genda, Takuya
author_facet Murata, Ayato
Angata, Kiyohiko
Sogabe, Maki
Sato, Shunsuke
Ichida, Takafumi
Narimatsu, Hisashi
Genda, Takuya
author_sort Murata, Ayato
collection PubMed
description BACKGROUND: Serum hepatitis B surface antigen (HBsAg) is a component of both hepatitis B virus (HBV) virions and non-infectious subviral particles (SVPs). Recently, O-glycosylation of the PreS2 domain of middle HBsAg protein has been identified as a distinct characteristic of genotype C HBV virions versus SVPs. This study aimed to evaluate serum O-glycosylated HBsAg levels in patients with chronic hepatitis B (CHB) treated with nucleos(t)ide analogs (NAs). METHODS: Forty-seven treatment-naïve patients with genotype C CHB were retrospectively enrolled. Serum O-glycosylated HBsAg levels at baseline and after 48 weeks of NA therapy were quantified by immunoassay using a monoclonal antibody against the O-glycosylated PreS2 domain of middle HBsAg, and their correlations with conventional HBV marker levels were analyzed. RESULTS: At baseline, the serum O-glycosylated HBsAg levels were significantly correlated with the HBV DNA (P = 0.004), HBsAg (P = 0.005), and hepatitis B-core related antigen (HBcrAg, P = 0.001) levels. Both HBV DNA and O-glycosylated HBsAg levels were decreased after 48 weeks of NA therapy. The significant correlation of the O-glycosylated HBsAg level with the HBsAg or HBcrAg level was lost in patients who achieved undetectable HBV DNA (HBsAg, P = 0.429; HBcrAg, P = 0.065). Immunoprecipitation assays demonstrated that HBV DNA and RNA were detected in the O-glycosylated HBsAg-binding serum fraction, and the proportion of HBV RNA increased during NA therapy (P = 0.048). CONCLUSION: Serum O-glycosylated HBsAg levels change during NA therapy and may reflect combined levels of serum HBV DNA and RNA virions. An O-glycosylated HBsAg-based immunoassay may provide a novel means to monitor viral kinetics during NA therapy.
format Online
Article
Text
id pubmed-9153111
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91531112022-06-01 Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy Murata, Ayato Angata, Kiyohiko Sogabe, Maki Sato, Shunsuke Ichida, Takafumi Narimatsu, Hisashi Genda, Takuya BMC Gastroenterol Research BACKGROUND: Serum hepatitis B surface antigen (HBsAg) is a component of both hepatitis B virus (HBV) virions and non-infectious subviral particles (SVPs). Recently, O-glycosylation of the PreS2 domain of middle HBsAg protein has been identified as a distinct characteristic of genotype C HBV virions versus SVPs. This study aimed to evaluate serum O-glycosylated HBsAg levels in patients with chronic hepatitis B (CHB) treated with nucleos(t)ide analogs (NAs). METHODS: Forty-seven treatment-naïve patients with genotype C CHB were retrospectively enrolled. Serum O-glycosylated HBsAg levels at baseline and after 48 weeks of NA therapy were quantified by immunoassay using a monoclonal antibody against the O-glycosylated PreS2 domain of middle HBsAg, and their correlations with conventional HBV marker levels were analyzed. RESULTS: At baseline, the serum O-glycosylated HBsAg levels were significantly correlated with the HBV DNA (P = 0.004), HBsAg (P = 0.005), and hepatitis B-core related antigen (HBcrAg, P = 0.001) levels. Both HBV DNA and O-glycosylated HBsAg levels were decreased after 48 weeks of NA therapy. The significant correlation of the O-glycosylated HBsAg level with the HBsAg or HBcrAg level was lost in patients who achieved undetectable HBV DNA (HBsAg, P = 0.429; HBcrAg, P = 0.065). Immunoprecipitation assays demonstrated that HBV DNA and RNA were detected in the O-glycosylated HBsAg-binding serum fraction, and the proportion of HBV RNA increased during NA therapy (P = 0.048). CONCLUSION: Serum O-glycosylated HBsAg levels change during NA therapy and may reflect combined levels of serum HBV DNA and RNA virions. An O-glycosylated HBsAg-based immunoassay may provide a novel means to monitor viral kinetics during NA therapy. BioMed Central 2022-05-31 /pmc/articles/PMC9153111/ /pubmed/35641912 http://dx.doi.org/10.1186/s12876-022-02352-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Murata, Ayato
Angata, Kiyohiko
Sogabe, Maki
Sato, Shunsuke
Ichida, Takafumi
Narimatsu, Hisashi
Genda, Takuya
Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
title Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
title_full Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
title_fullStr Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
title_full_unstemmed Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
title_short Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
title_sort serum o-glycosylated hepatitis b surface antigen levels in patients with chronic hepatitis b during nucleos(t)ide analog therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153111/
https://www.ncbi.nlm.nih.gov/pubmed/35641912
http://dx.doi.org/10.1186/s12876-022-02352-4
work_keys_str_mv AT murataayato serumoglycosylatedhepatitisbsurfaceantigenlevelsinpatientswithchronichepatitisbduringnucleostideanalogtherapy
AT angatakiyohiko serumoglycosylatedhepatitisbsurfaceantigenlevelsinpatientswithchronichepatitisbduringnucleostideanalogtherapy
AT sogabemaki serumoglycosylatedhepatitisbsurfaceantigenlevelsinpatientswithchronichepatitisbduringnucleostideanalogtherapy
AT satoshunsuke serumoglycosylatedhepatitisbsurfaceantigenlevelsinpatientswithchronichepatitisbduringnucleostideanalogtherapy
AT ichidatakafumi serumoglycosylatedhepatitisbsurfaceantigenlevelsinpatientswithchronichepatitisbduringnucleostideanalogtherapy
AT narimatsuhisashi serumoglycosylatedhepatitisbsurfaceantigenlevelsinpatientswithchronichepatitisbduringnucleostideanalogtherapy
AT gendatakuya serumoglycosylatedhepatitisbsurfaceantigenlevelsinpatientswithchronichepatitisbduringnucleostideanalogtherapy